Common
Dostarlimab
Medication for endometrial cancer treatment
Dostarlimab
Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer and rectal cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody. The most common side effects reported in the US include fatigue/asthenia, nausea, diarrhea, anemia, and constipation. Additional side effects reported in the European Union include vomiting, joint pain, itching, rash, fever, and hypothyroidism (low levels of thyroid hormones).
Open boosters, collect cards and trade them. Free to play.
Play for free